These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
185 related articles for article (PubMed ID: 32053082)
1. Proteomic Level Changes on Treatment in MCF-7/DDP Breast Cancer Drug- Resistant Cells. Jin G; Wang K; Liu Y; Liu X; Zhang X; Zhang H Anticancer Agents Med Chem; 2020; 20(6):687-699. PubMed ID: 32053082 [TBL] [Abstract][Full Text] [Related]
2. Induction of Necroptosis in Human Breast Cancer Drug-Resistant Cells by SMAC Analog LCL161 After Caspase Inhibition Requires RIP3. Jin G; Liu Y; Xu P; Jin G Pharmazie; 2019 Jun; 74(6):363-368. PubMed ID: 31138375 [TBL] [Abstract][Full Text] [Related]
3. Smac mimetic‑induced caspase‑independent necroptosis requires RIP1 in breast cancer. Jin G; Lan Y; Han F; Sun Y; Liu Z; Zhang M; Liu X; Zhang X; Hu J; Liu H; Wang B Mol Med Rep; 2016 Jan; 13(1):359-66. PubMed ID: 26573429 [TBL] [Abstract][Full Text] [Related]
4. Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma. Ramakrishnan V; Gomez M; Prasad V; Kimlinger T; Painuly U; Mukhopadhyay B; Haug J; Bi L; Rajkumar SV; Kumar S Oncotarget; 2016 Aug; 7(35):56253-56265. PubMed ID: 27494845 [TBL] [Abstract][Full Text] [Related]
5. Induction of interferon-β and interferon signaling by TRAIL and Smac mimetics via caspase-8 in breast cancer cells. Granqvist V; Holmgren C; Larsson C PLoS One; 2021; 16(3):e0248175. PubMed ID: 33770100 [TBL] [Abstract][Full Text] [Related]
6. The SMAC mimetic LCL161 is a direct ABCB1/MDR1-ATPase activity modulator and BIRC5/Survivin expression down-regulator in cancer cells. Chang YC; Kondapuram SK; Yang TH; Syed SB; Cheng SM; Lin TY; Lin YC; Coumar MS; Chang JY; Leung E; Cheung CHA Toxicol Appl Pharmacol; 2020 Aug; 401():115080. PubMed ID: 32497533 [TBL] [Abstract][Full Text] [Related]
7. Inhibitor of apoptosis proteins as therapeutic targets in multiple myeloma. Ramakrishnan V; Painuly U; Kimlinger T; Haug J; Rajkumar SV; Kumar S Leukemia; 2014 Jul; 28(7):1519-28. PubMed ID: 24402161 [TBL] [Abstract][Full Text] [Related]
8. LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC. Yang C; Wang H; Zhang B; Chen Y; Zhang Y; Sun X; Xiao G; Nan K; Ren H; Qin S J Exp Clin Cancer Res; 2016 Sep; 35(1):158. PubMed ID: 27737687 [TBL] [Abstract][Full Text] [Related]
9. Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis. Chen J; Wang W; Wang H; Liu X; Guo X Drug Discov Ther; 2014 Feb; 8(1):33-41. PubMed ID: 24647156 [TBL] [Abstract][Full Text] [Related]
10. Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer. Lee KM; Lee H; Han D; Moon WK; Kim K; Oh HJ; Choi J; Hwang EH; Kang SE; Im SA; Lee KH; Ryu HS Breast Cancer Res; 2020 Nov; 22(1):130. PubMed ID: 33239070 [TBL] [Abstract][Full Text] [Related]
11. [Effects of LCL161, a Smac mimetic on the proliferation and apoptosis in hepatocellular carcinoma cells]. Ren K; Ma L; Chong D; Zhang Z; Zhou C; Liu H; Zhao S Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2016 Sep; 41(9):898-904. PubMed ID: 27640787 [TBL] [Abstract][Full Text] [Related]
13. Nuclear factor-κB signaling inhibitors revert multidrug-resistance in breast cancer cells. Abdin SM; Tolba MF; Zaher DM; Omar HA Chem Biol Interact; 2021 May; 340():109450. PubMed ID: 33775688 [TBL] [Abstract][Full Text] [Related]
14. Effects of endoplasmic reticulum stress on the autophagy, apoptosis, and chemotherapy resistance of human breast cancer cells by regulating the PI3K/AKT/mTOR signaling pathway. Zhong JT; Yu J; Wang HJ; Shi Y; Zhao TS; He BX; Qiao B; Feng ZW Tumour Biol; 2017 May; 39(5):1010428317697562. PubMed ID: 28459209 [TBL] [Abstract][Full Text] [Related]
15. Cytotoxic effects of SMAC-mimetic compound LCL161 in head and neck cancer cell lines. Brands RC; Herbst F; Hartmann S; Seher A; Linz C; Kübler AC; Müller-Richter UDA Clin Oral Investig; 2016 Dec; 20(9):2325-2332. PubMed ID: 26846923 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of Bcl-2 improves effect of LCL161, a SMAC mimetic, in hepatocellular carcinoma cells. Chen KF; Lin JP; Shiau CW; Tai WT; Liu CY; Yu HC; Chen PJ; Cheng AL Biochem Pharmacol; 2012 Aug; 84(3):268-77. PubMed ID: 22580047 [TBL] [Abstract][Full Text] [Related]
17. Wogonin induces apoptosis and down-regulates survivin in human breast cancer MCF-7 cells by modulating PI3K-AKT pathway. Huang KF; Zhang GD; Huang YQ; Diao Y Int Immunopharmacol; 2012 Feb; 12(2):334-41. PubMed ID: 22182776 [TBL] [Abstract][Full Text] [Related]
18. Smac mimetic compound LCL161 sensitizes esophageal carcinoma cells to radiotherapy by inhibiting the expression of inhibitor of apoptosis protein. Qin Q; Zuo Y; Yang X; Lu J; Zhan L; Xu L; Zhang C; Zhu H; Liu J; Liu Z; Tao G; Dai S; Zhang X; Ma J; Cai J; Sun X Tumour Biol; 2014 Mar; 35(3):2565-74. PubMed ID: 24170321 [TBL] [Abstract][Full Text] [Related]
19. Caspase-dependent and caspase-independent induction of apoptosis in breast cancer by fucoidan via the PI3K/AKT/GSK3β pathway in vivo and in vitro. Xue M; Ji X; Xue C; Liang H; Ge Y; He X; Zhang L; Bian K; Zhang L Biomed Pharmacother; 2017 Oct; 94():898-908. PubMed ID: 28810530 [TBL] [Abstract][Full Text] [Related]
20. Vincristine resistance in relapsed neuroblastoma can be efficiently overcome by Smac mimetic LCL161 treatment. Frommann K; Appl B; Hundsdoerfer P; Reinshagen K; Eschenburg G J Pediatr Surg; 2018 Oct; 53(10):2059-2064. PubMed ID: 29455885 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]